Multiple Ascending Dose Study of CG200745 'Ivaltinostat' Oral Capsule

NCT05716919 | Unknown Phase 1

• 1 other identifier: CG200745-1-02
• Study Type: interventional
• Target: 32
• Locations: 1 country
• Sites: 1

Brief Summary

A Phase I, Double blind, Randomized, Placebo-controlled, Multiple Ascending Dose Study to evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Orally Administered 'CG-745' Capsule in Healthy Male Volunteers

Conditions

Hematologic Malignancy; Solid Tumor; Fibrosis

Outcome Measures

Primary Outcomes (2)

• Plasma Pharmacokinetic measures (Cmax, Cmax-ss)

  up to 4 weeks

• Plasma Pharmacokinetic measures (AUC max, AUCmax-ss)

  up to 4 weeks

Secondary Outcomes (1)

• The Number of Participants Who Experienced Serious or Non-Serious Adverse Events

  Up to 4 weeks for each dosing cohort

Study Arms (2)

Cohort 1 - 4

EXPERIMENTAL

Cohort 1 : 50 mg/day Cohort 2 : 100 mg/day Cohort 3: 200mg/day \[Cohort 4: 300mg/day: based on the result of Safety Review Meeting (SRM)\]

Drug: Ivaltinostat

Placebo

PLACEBO COMPARATOR

Other: Placebo

Interventions

Ivaltinostat DRUG

Ivaltinostat capsule

Cohort 1 - 4

Placebo OTHER

Placebo capsule

Placebo

Eligibility Criteria

• Age: 19 Years - 50 Years
• Sex: male
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Patients who are between 19 to 50 years of age at screening visit.
• Patients who have body weight between 50.0 to 90.0 kg, and Body Mass Index (BMI) of 18.0 to 30.0 kg/m2 at screening visit.
• ☞ BMI (kg/m2) = Body Weight (kg) / {Height(m)}2
• Patients who have signed informed consent prior to study participation after receiving detailed information on the purpose and details of the study, the characteristics of the test drug, and the expected adverse events.
• Patients who are determined to be eligible by the investigator after evaluation of the following screening results: study questionnaires, physical examination, laboratory test, electrocardiogram, vital signs).

You may not qualify if:

• Medical history of clinically significant hepatic, renal, neurological, respiratory, endocrine, hematological, oncological, cardiovascular, urinary, and/or psychiatric disorder.
• History of gastrointestinal disease or gastrointestinal surgery (except for simple appendectomy or hernia operation) that may affect the pharmacokinetic and/or safety evaluation of IP medications.
• Known clinically significant hypersensitivity to HDAC inhibitors and/or other drugs.
• Systolic blood pressure (SBP) less than 90 mmHg or over 140 mmHg; diastolic blood pressure (DBP) less than 50 mmHg or over 95 mmHg; pulse rate less than 45/min or over 100/min in the sitting position after a 5-minute rest.
• Patients who show one or more of the following findings during screening (including additional tests):
• AST (GOT) or ALT (GPT) exceeds 1.5 times the upper limit of the normal range ② Total bilirubin exceeds 1.5 times the upper limit of the normal range ③ Absolute neutrophil count (ANC) lower than 2,000/uL ④ Hb less than 12.5 g/dL ⑤ Platelets count less than 130,000/uL
• Participation in another clinical study or bioequivalence study within 180 days prior to the first IP administration.
• Positive result in serum tests (hepatitis B, hepatitis C, human immunodeficiency virus, and syphilis).
• Donation of whole blood within 60 days, apheresis within 30 days, or transfusion within 30 days prior to the first IP administration.
• Exposure to prescribed medications or herbal medicines 2 weeks prior to the first IP administration, or any general medication (OTC drug), health supplements, and/or vitamin supplements within 1 week prior to the first investigational product administration (the subject may still participate if the principal investigator determines that the subject is eligible for enrollment).
• History of heavy smoking (more than 10 cigarettes/day) within three months prior to the first IP administration, or positive test result in urine cotinine test.
• Excessive caffeine intake (\> 5 units/day, 1 unit = 100 mg), excessive alcohol intake (\> 21 units/week, 1 unit = 10 g of pure alcohol), or inability to abstain from drinking during admission period.
• Inability to use a medically acceptable contraceptive method\* for the duration of the study and up to 3 months after the last IP administration.
• \* Medically acceptable contraception:
• Use of intrauterine device (by spouse or partner) with a proven pregnancy prevention rate.

Sponsors & Collaborators

• Machaon Biotherapeutics, Inc.: lead

Study Sites (1)

Seoul National University Hospital

Seoul, South Korea

Location

MeSH Terms

Conditions

Hematologic Neoplasms; Fibrosis

Interventions

N1-(3-(dimethylamino)propyl)-N8-hydroxy-2-((naphthalene-1-loxy)methyl)oct-2-enediamide

Condition Hierarchy (Ancestors)

Neoplasms by Site; Neoplasms; Hematologic Diseases; Hemic and Lymphatic Diseases; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: SEQUENTIAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 30, 2023
• First Posted: February 8, 2023
• Study Start: March 9, 2023
• Primary Completion: December 1, 2023
• Study Completion: December 1, 2023
• Last Updated: October 23, 2023

Record last verified: 2023-10

Locations

KR (1)